Lead Product(s): 2G-Dabocins
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Organovo Holdings
Deal Size: $11.9 million Upfront Cash: Undisclosed
Deal Type: Investment January 06, 2020
This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.